Cytokeratin Fragment 19(CYFRA 21-1) as a Tumor Marker in Non - Small Cell Lung Cancer

評估CYFRA 21-1作為非小細胞肺癌腫瘤標誌之價值

黃明賢(Ming-Shyan Huang) ； 鍾相彬(Shiang-Bin Jong) ； 林茂生(Maw-Sheng Lin) ； 鍾飲文(Inn-Wen Chong) ； 蔡米山(Mee-Sun Tsai) ； 林秀純(Hsiu-Chun Lin) ； 黃吉志(Jhi-Jhu Hwang)

《The Kaohsiung Journal of Medical Sciences》 12卷2期 (1996/02) Pp. 62-68

https://doi.org/10.6452/KJMS.199602.0062

摘要

To evaluate the diagnostic value of the serum cytokeratin 19 fragment (CYFRA 21-1) in bronchogenic carcinoma, we investigated the sera of 138 patients (58 with benign pulmonary disease and 80 with non-small cell lung cancer (NSCLC) using immunoradiometric assay. The mean (SD) value of serum CYFRA 21.1 in NSCLC (13.26(16.54)) was significantly higher than in benign lung diseases (1.74(1.55))(p＜0.0001).Sensitivity for CYFRA 21-1 (using 3.5 ng/ml, a cut-off value corresponding to a 95% specifictity for benign pulmonary disease) in NSLC was 62%. Positive CYFRA 21-1 levels were significantly higher in 75% of patients with squamous cell carcinoma (n=36) than in 53% with other NSCLC (n=44)(p＜0.05). CYFRA 21-1 levels were significantly different between squamous cell carcinoma (17.28(19.94)) and the other NSCLC (9.96(12.44))(p＜0.05). Elevated CYFRA 21-1 levels in patients with stage III and IV disease (n=64, 18.19(26.51)) were significantly higher than in stage I and II(n=16, 4.41(5.76))(p＜0.02). The positive rate of CYFRA 21-1 in tumor stage I and II was only 37%. Our results indicate that CYFRA 21-1 may be a useful tumor marker in NSCLC,, especially in squamous cell carcinoma. However, CYFRA 21-1 cannot be used for the diagnosis of early stage disease of NSCLC. CYFRA 21-1 may also contribute to the monitoring of NSCLC.

並列摘要

To evaluate the diagnostic value of the serum cytokeratin 19 fragment (CYFRA 21-1) in bronchogenic carcinoma, we investigated the sera of 138 patients (58 with benign pulmonary disease and 80 with non-small cell lung cancer (NSCLC) using immunoradiometric assay. The mean (SD) value of serum CYFRA 21.1 in NSCLC (13.26(16.54)) was significantly higher than in benign lung diseases (1.74(1.55))(p＜0.0001).Sensitivity for CYFRA 21-1 (using 3.5 ng/ml, a cut-off value corresponding to a 95% specifictity for benign pulmonary disease) in NSLC was 62%. Positive CYFRA 21-1 levels were significantly higher in 75% of patients with squamous cell carcinoma (n=36) than in 53% with other NSCLC (n=44)(p＜0.05). CYFRA 21-1 levels were significantly different between squamous cell carcinoma (17.28(19.94)) and the other NSCLC (9.96(12.44))(p＜0.05). Elevated CYFRA 21-1 levels in patients with stage III and IV disease (n=64, 18.19(26.51)) were significantly higher than in stage I and II(n=16, 4.41(5.76))(p＜0.02). The positive rate of CYFRA 21-1 in tumor stage I and II was only 37%. Our results indicate that CYFRA 21-1 may be a useful tumor marker in NSCLC,, especially in squamous cell carcinoma. However, CYFRA 21-1 cannot be used for the diagnosis of early stage disease of NSCLC. CYFRA 21-1 may also contribute to the monitoring of NSCLC.

並列關鍵字

CYFRA 21-1 ； non-small cell lung cancer